Target intelligence / Profile preview

Poloxamer 181

Molecular classification
Other (Triblock copolymer), Synthetic nonionic surfactant, Excipients, Polyoxypropylene-polyoxyethylene block copolymer
01

Overview

Poloxamer 181 is a synthetic, nonionic surfactant belonging to the poloxamer family, composed of a central hydrophobic polyoxypropylene chain flanked by two hydrophilic polyoxyethylene chains. It is commonly sold under the trade names Pluronic L-61 and Synperonic L61, and is used primarily as a solubilizing agent, emulsifier, and excipient in industrial, cosmetic, and pharmaceutical applications. Its key technological properties include temperature- and concentration-dependent micelle and gel formation, which can be useful for drug delivery purposes. While poloxamers including 181 have been evaluated for enhancing drug delivery and sensitizing drug-resistant cancers, they are not themselves therapeutic molecular targets, receptors, or enzymes.

Other names
Pluronic L-61Synperonic L61Spectrum Poloxamer 181
02

Mechanism of action

Functions by forming micelles that encapsulate hydrophobic drugs, thereby increasing their solubility, bioavailability, and delivery. Can sensitize resistant cancer cells, likely by modifying cellular uptake through membrane effects.

03

Biological functions

Solubilization of poorly soluble drugsEmulsificationDetergent/surfactantDrug delivery enhancement (especially for chemotherapy resistance reversal)Formation of micelles and gels for controlled drug release
04

Disease associations

Other (Pharmaceutical technology; shown to sensitize drug resistant cancers to chemotherapy in formulation studies)
05

Safety considerations

Generally considered safe for industrial and research purposes, but not all grades are suitable for human consumption or therapeutic useMay contain trace contaminants (ethylene oxide, propylene oxide, and 1,4-dioxane) that present potential toxicity concernsMay cause skin irritationNot considered carcinogenicNo robust data on reproductive or developmental toxicity
06

Interacting drugs

No direct drug-receptor interactions

2 more in the full profile.

Beyond the preview

Go deeper on Poloxamer 181.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poloxamer 181.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call